Intractable epilepsies. An open trial with Clobazam. 1989

C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi

Clobazam was used as an added treatment in 28 patients with intractable epilepsies: 26 subjects had associated handicaps. A good response was observed during the first two-three months of Clobazam treatment: the reduction in seizure frequency of 73% for partial seizures and 62% for GTCs. A tolerance to Clobazam treatment was observed after the third month of treatment: at the end of the sixth month, the seizure frequency was reduced to 36% for partial seizures and 39% for GTCs. Out of 28 patients 4 were seizure free at the end of the sixth month; we have not found any specific characteristic in these patients. The AA. suggest the possibility of an intermittent use of Clobazam for this type of patients.

UI MeSH Term Description Entries
D008297 Male Males
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078306 Clobazam A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY. 1-Phenyl-5-methyl-8-chloro-1,2,4,5- tetrahydro-2,4-diketo-3H-1,5-benzodiazepine,Frisium,HR 376,LM-2717,Onfi,Urbanyl,LM 2717,LM2717
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D001570 Benzodiazepinones

Related Publications

C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
June 2011, Seizure,
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
April 1983, Presse medicale (Paris, France : 1983),
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
January 1982, Brain & development,
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
January 1984, Revista chilena de pediatria,
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
May 1995, Journal of child neurology,
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
August 1990, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
March 1993, Arquivos de neuro-psiquiatria,
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
October 1995, Journal of the American Academy of Dermatology,
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
October 1981, Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression,
C M Cornaggia, and G Cattabeni, and N Cerisola, and C Leozappa, and P L Mascetti, and R Massironi, and G Porro, and E Manghi
November 2003, Expert review of neurotherapeutics,
Copied contents to your clipboard!